Literature DB >> 10770783

Bioavailability of once- and twice-daily regimens of didanosine in human immunodeficiency virus-infected children.

T Abreu1, K Plaisance, V Rexroad, S Nogueira, R H Oliveira, L A Evangelista, R Rangel, I S Silva, C Knupp, J S Lambert.   

Abstract

The bioavailability of didanosine at 180 mg/m(2) once daily was compared to that at 90 mg/m(2) twice daily in 24 children with advanced human immunodeficiency virus infection. Children were studied at steady state using optimal sampling and prior pharmacokinetic parameter estimates. Relative bioavailability was 0. 95 +/- 0.49, supporting the potential clinical adequacy of once-daily dosing.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10770783      PMCID： PMC89876          DOI： 10.1128/AAC.44.5.1375-1376.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Once-daily administration of didanosine in combination with stavudine in antiretroviral-naive patients. The STADI Group.

Authors:  J Reynes; R Denisi; P Massip; J Izopet; I Pellegrin; M Segondy
Journal:  J Acquir Immune Defic Syndr       Date:  1999-09-01       Impact factor: 3.731

2.  Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: pharmacokinetic properties, safety, and immunologic and virologic effects.

Authors:  M W Kline; C V Fletcher; M E Federici; A T Harris; K D Evans; V L Rutkiewicz; W T Shearer; L M Dunkle
Journal:  Pediatrics       Date:  1996-06       Impact factor: 7.124

3.  Comparison of the plasma pharmacokinetics and renal clearance of didanosine during once and twice daily dosing in HIV-1 infected individuals.

Authors:  R M Hoetelmans; R P van Heeswijk; M Profijt; J W Mulder; P L Meenhorst; J M Lange; P Reiss; J H Beijnen
Journal:  AIDS       Date:  1998-12-03       Impact factor: 4.177

4.  Clinical pharmacology of 2',3'-dideoxyinosine in human immunodeficiency virus-infected children.

Authors:  F M Balis; P A Pizzo; K M Butler; M E Hawkins; P Brouwers; R N Husson; F Jacobsen; S M Blaney; J Gress; P Jarosinski
Journal:  J Infect Dis       Date:  1992-01       Impact factor: 5.226

5.  Dideoxyinosine in children with symptomatic human immunodeficiency virus infection.

Authors:  K M Butler; R N Husson; F M Balis; P Brouwers; J Eddy; D el-Amin; J Gress; M Hawkins; P Jarosinski; H Moss
Journal:  N Engl J Med       Date:  1991-01-17       Impact factor: 91.245

6.  2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial.

Authors:  J S Lambert; M Seidlin; R C Reichman; C S Plank; M Laverty; G D Morse; C Knupp; C McLaren; C Pettinelli; F T Valentine
Journal:  N Engl J Med       Date:  1990-05-10       Impact factor: 91.245

Review 7.  Didanosine. An update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease.

Authors:  C M Perry; J A Balfour
Journal:  Drugs       Date:  1996-12       Impact factor: 9.546

8.  Pharmacokinetic evaluation of the combination of zidovudine and didanosine in children with human immunodeficiency virus infection.

Authors:  B U Mueller; P A Pizzo; M Farley; R N Husson; J Goldsmith; A Kovacs; L Woods; J Ono; J A Church; P Brouwers
Journal:  J Pediatr       Date:  1994-07       Impact factor: 4.406

9.  Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection.

Authors:  D Gibb; M Barry; S Ormesher; L Nokes; M Seefried; C Giaquinto; D Back
Journal:  Br J Clin Pharmacol       Date:  1995-05       Impact factor: 4.335

10.  Impact of bioavailability on determination of the maximal tolerated dose of 2',3'-dideoxyinosine in phase I trials.

Authors:  G L Drusano; G J Yuen; G Morse; T P Cooley; M Seidlin; J S Lambert; H A Liebman; F T Valentine; R Dolin
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191
View more
  5 in total

Review 1.  Pharmacokinetics of antiretroviral therapy in HIV-1-infected children.

Authors:  Pieter L A Fraaij; Jeroen J A van Kampen; David M Burger; Ronald de Groot
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 2.  Antiretroviral drugs in pediatric HIV-infected patients: pharmacokinetic and practical challenges.

Authors:  B Ryan Phelps; Natella Rakhmanina
Journal:  Paediatr Drugs       Date:  2011-06-01       Impact factor: 3.022

3.  Pharmacokinetics of stavudine and didanosine coadministered with nelfinavir in human immunodeficiency virus-exposed neonates.

Authors:  C Rongkavilit; P Thaithumyanon; T Chuenyam; B D Damle; S Limpongsanurak; C Boonrod; A Srigritsanapol; E A Hassink; R M Hoetelmans; D A Cooper; J M Lange; K Ruxrungtham; P Phanuphak
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

4.  Didanosine population pharmacokinetics in West African human immunodeficiency virus-infected children administered once-daily tablets in relation to efficacy after one year of treatment.

Authors:  Déborah Hirt; Christophe Bardin; Serge Diagbouga; Boubacar Nacro; Hervé Hien; Emmanuelle Zoure; François Rouet; Adama Ouiminga; Saik Urien; Vincent Foulongne; Philippe Van De Perre; Jean-Marc Tréluyer; Philippe Msellati
Journal:  Antimicrob Agents Chemother       Date:  2009-07-06       Impact factor: 5.191

Review 5.  Nucleoside and nucleotide reverse transcriptase inhibitors in children.

Authors:  Carlo Giaquinto; Osvalda Rampon; Martina Penazzato; Federica Fregonese; Anita De Rossi; Ruggiero D'Elia
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.